Related by context. All words. (Click for frequent words.) 77 Events MACE 71 Kaplan Meier estimates 67 Reduce Cardiovascular 66 MACCE 66 Aranesp Therapy 66 Myocardial Infarction Study 66 periprocedural 65 XIENCE V PROMUS Stent 65 thromboembolic 64 ipsilateral stroke 63 Thrombolysis 63 target lesion revascularization 63 TAXUS Stent 63 Acute Myocardial Infarction 63 Patient Outcomes 63 SPIRIT FIRST 63 Skeletal Related 63 myocardial infarction stroke 63 platelet reactivity 62 binary restenosis 62 Angiographic 62 Erythropoietic therapies may 62 reinfarction 62 nonfatal myocardial infarction 62 perioperative mortality 62 Coronary Artery Bypass Graft 62 STRIDE PD 61 repeat revascularization 61 carotid endarterectomy CEA 61 Secondary endpoints 61 ischemia driven 61 discontinuations due 61 confirmed thrombotic cardiovascular 61 RECIST Response Evaluation Criteria 61 Primary endpoints 61 Free Survival PFS 61 Unstable Angina 61 specific antigen PSA 61 unstable angina pectoris 61 EVEREST II 61 atherothrombotic disease 61 HBeAg seroconversion 61 Echocardiographic 61 unfractionated heparin UFH 61 carotid artery stenting CAS 60 composite endpoint 60 Crohn Disease Activity 60 postintervention 60 Stent thrombosis 60 sirolimus eluting stents 60 Secondary endpoints included 60 Renal Insufficiency 60 demonstrated clinically meaningful 60 Kaplan Meier analysis 60 bypass graft CABG surgery 60 recurrent ischemic 60 serum phosphorous 60 postoperative mortality 60 ischemic complications 60 severe hypoglycemic 60 coronary revascularization 60 Cypher Stent 60 definite stent thrombosis 59 EURIDIS 59 Secondary endpoints include 59 SVR# 59 thromboembolic events 59 PROactive PROspective Clinical Trial 59 biochemical recurrence 59 VT VF 59 DES implantation 59 estimated glomerular filtration 59 Pharmacokinetic 59 TAXUS Express Stent 59 Randomized Evaluation 59 acute coronary 59 myocardial infarction MI 59 Acute Coronary Syndrome 59 cerebrovascular events 59 Atherosclerotic 59 TAXUS p value 59 multicenter multinational 59 Breast Density 59 Secondary efficacy endpoints 59 Patients Receiving 59 Ischaemic 59 XIENCE V demonstrated 59 confirmed CCyR 59 PROactive 59 Cardiotoxicity 59 ARCOXIA 59 oral FTY# 59 Target Lesion Revascularization TLR 59 ST Segment Elevation 59 See CLINICAL PHARMACOLOGY 59 adenoma recurrence 59 NIHSS 59 Percutaneous Coronary Intervention 59 tumor lysis syndrome 59 RECORD1 59 zotarolimus eluting stent 59 Acute Ischemic Stroke 59 Solid Tumors 59 Microalbuminuria 59 hemorrhagic complications 58 underwent resection 58 β blockers 58 venous thromboembolic disease 58 primary patency 58 secondary endpoint 58 Patency 58 recurrent venous thromboembolism 58 symptomatic VTE 58 endoscopic remission 58 Decompensated Heart Failure 58 FDG-PET/CT 58 LV dysfunction 58 Val HeFT 58 neointimal hyperplasia 58 morphometric vertebral fractures 58 Scale EDSS 58 arterial thromboembolic events 58 IIIa inhibitor 58 sirolimus eluting stent 58 reintervention 58 treatment emergent adverse 58 TAXUS ATLAS 58 nonfatal MI 58 LVEF 58 CYPHER ® Stent 58 intracoronary 58 pharmacokinetic PK 58 oxycodone CR 58 ACUITY trial 58 paclitaxel eluting stents 58 Prognostic Value 58 primary percutaneous coronary 58 ischemic cardiomyopathy 58 Coronary artery bypass grafting 58 macrovascular events 58 peri procedural 58 HF hospitalization 58 sustained virological response 58 prospectively stratified 58 Taxus Stent 58 Pain Intensity 58 spinal cord compression 58 annualized relapse 58 Lp PLA 2 58 Clinical Outcome 58 TAXUS Liberté stent 58 Kaplan Meier 58 tipranavir r 58 intravascular hemolysis 58 revascularisation 58 lumbar spine BMD 58 Ischemic 58 SYNTAX trial 58 Endarterectomy 58 ENDEAVOR II 58 Coronary Tree 58 CARE HF 58 prospectively defined 58 serologically active patients 58 recurrent ischemia 58 CCyR 58 FOLPI 58 tirofiban 58 Hematologic 57 NCCTG N# 57 deep venous thromboses 57 Cardiac Resynchronization 57 ischemic cardiovascular 57 angiographic outcomes 57 Left Ventricular 57 Upcoming BIO 57 FluCAM arm 57 apnea hypopnea 57 Prospective Randomized 57 serum prostate 57 SYNTAX 57 acute coronary syndromes ACS 57 ARIXTRA 57 CIMZIA TM certolizumab pegol 57 secondary efficacy endpoint 57 Carotid Stenting 57 Alzheimer Disease Assessment 57 Index CDAI 57 postoperative AF 57 MEND CABG 57 Carotid Endarterectomy 57 thromboembolism 57 mean ± SEM 57 mm Stent 57 HES CEL 57 Relapsing Multiple Sclerosis 57 nondiabetic patients 57 HORIZONS AMI trial 57 macrovascular 57 variceal bleeding 57 inhospital 57 Main Outcome Measures 57 postoperative complication 57 Intracranial 57 rehospitalization 57 Edge STudy 57 SORT OUT III 57 FDA defined valvulopathy 57 Coronary Artery Calcium 57 RE LY ® 57 cobiprostone 57 Oral Fingolimod 57 systemic embolism 57 secondary efficacy endpoints 57 Myocardial Infarction 57 events MACE 57 Folfox 57 bivalirudin monotherapy 57 APTIVUS r 57 ventricular tachyarrhythmia 57 neoadjuvant 57 ACR# response 57 thromboembolic complications 57 preintervention 57 sternal wound infection 57 Lupuzor ™ 57 cardiovascular hospitalization 57 WOMAC pain 57 LVSD 57 Brief Psychiatric 57 rosuvastatin #mg 57 Outcome Measures 57 periprocedural MI 57 doxorubicin docetaxel 57 Pioglitazone 57 Acute Coronary Syndromes 57 Restenosis 57 Hormone Refractory Prostate Cancer 57 Cardiovascular Risk 57 Bivalirudin 57 Veeco Upcoming Investor 57 Bone Metastases 57 calculated creatinine clearance 57 colorectal adenoma 57 Main Outcome Measure 57 asymptomatic carotid stenosis 57 Long Lesion 57 prespecified secondary 57 nonfatal myocardial infarction MI 56 stent binary restenosis 56 XIENCE V vs. 56 Montgomery Asberg Depression 56 repeat paracentesis 56 Carotid Revascularization Endarterectomy vs. 56 myocardial necrosis 56 nonfatal stroke 56 ATACAND 56 Histologic 56 Hypotension 56 Infarction 56 ADAS cog 56 angioplasty stenting 56 severe exacerbations 56 PSA nadir 56 ventricular tachycardia VT 56 fondaparinux 56 fibrinolysis 56 Ejection Fraction 56 intima media thickness IMT 56 everolimus eluting stents 56 serum urate 56 virologic failure 56 rebleeding 56 Randomized controlled 56 HSCT 56 atherothrombotic 56 TAXUS Element Stent 56 TAXUS 56 Prostatectomy 56 Risk Stratification 56 Acute Decompensated Heart Failure 56 Stent Restenosis 56 Stenting 56 CK MB 56 rFVIIa 56 biochemical relapse 56 Cholesterol Levels SPARCL 56 carotid intima media 56 pT2 56 prospective multicentre 56 serum urate levels 56 Thromboembolism 56 Aggressive Reduction 56 insulin detemir 56 sUA 56 cTnT levels 56 clinically evaluable patients 56 PSADT 56 Polyp Prevention Trial 56 Subgroup Analysis 56 venous thromboembolic 56 TRITON TIMI 56 pericardial effusion 56 prolonged QT interval 56 severe neutropenia 56 recanalization 56 myocardial infarction ventricular fibrillation 56 pulmonary capillary wedge 56 DAS# scores 56 Insulin Therapy 56 PROactive study 56 assessing T DM1 56 serum phosphate 56 Carotid Artery Stenting 56 Invasive Breast Cancer 56 NATRECOR R 56 lopinavir r arm 56 left ventricular LV 56 sustained virologic response 56 Educational Exhibitions 56 SABCS 56 lispro 56 REYATAZ r 56 Tumor Response 56 Phase III AFFIRM 56 postprocedure 56 RE LY 56 CYPHER R Sirolimus eluting 56 PASI scores 56 linaclotide treated 56 6MWD 56 hematological parameters 56 Severity MSCS score 56 fasting plasma glucose 56 Castration Resistant Prostate Cancer 56 subtrochanteric 56 Response Evaluation Criteria 56 NSTE ACS 56 nadroparin 56 MADIT II 56 CR nPR 56 HCV RESPOND 2 56 patients undergoing CABG 56 DAS# CRP 56 intima media thickness 56 mL/min/#.# m 2 56 Myocardial Infarction TIMI 56 PCWP 56 Statistically Significant 56 Multicenter Automatic Defibrillator Implantation 56 ExTRACT TIMI 56 SELENA SLEDAI 56 thrombocytopenic 56 placebo fluoxetine 56 stent thrombosis 56 NYHA functional class 56 Unified Parkinson Disease 56 Forced Vital 56 hip BMD 55 fraction LVEF 55 TIMI 55 Treatment Outcome 55 syncopal 55 ENDEAVOR IV 55 Rating Scale UPDRS 55 preoperative PSA 55 prespecified 55 Spine Patient Outcomes 55 virological response 55 bortezomib refractory 55 non valvular atrial 55 recurrent DVT 55 Physical Function 55 Endocrine Therapy 55 diameter stenosis 55 pCR 55 neoadjuvant therapy 55 clinically localized prostate 55 Atrial 55 lipid parameters 55 ximelagatran 55 recurrent myocardial infarction 55 nonrandomized 55 graft occlusion 55 Revascularization 55 Solid Tumors criteria 55 NMIBC 55 advanced adenoma 55 thrombotic events 55 angiographic restenosis 55 relapsed MCL 55 virologic response 55 tolvaptan 55 Postoperative 55 p = NS 55 debulking surgery 55 baseline FEV 55 TURBT 55 Kidney Function 55 stent implantation 55 upper gastrointestinal bleeding 55 Subgroup analyzes 55 cerebrovascular accidents 55 infarct size 55 glomerular filtration 55 lactate dehydrogenase LDH 55 serum potassium 55 silent ischemia 55 IIIa inhibitors 55 nonobstructive CAD 55 Rating Scale MADRS 55 relapsed MM 55 TAXUS Liberte Long 55 cardiovascular hospitalizations 55 Score TOS 55 mcg QD 55 iPTH 55 sirolimus stent 55 QTc 55 haemodynamic 55 intracerebral haemorrhage 55 dose atorvastatin 55 lipid lowering drugs 55 coinfected patients 55 pT3 55 acute myocardial infarction AMI 55 Score IPSS 55 recurrent VTE 55 complete cytogenetic response 55 cTnI 55 tapentadol ER 55 glycosylated hemoglobin HbA1c 55 cerebrovascular adverse 55 cytogenetic response 55 underwent percutaneous coronary 55 evaluable 55 stent thromboses 55 KIF6 carriers 55 systolic hypertension 55 Left Atrial 55 atherothrombosis 55 reoperation 55 specified primary endpoint 55 OPCAB 55 Skin sterol 55 Postmarketing 55 Expanded Disability Status 55 COPERNICUS 55 beta blocker therapy 55 GERD symptom 55 undergoing coronary artery 55 LEXIVA r 55 TAXUS stent 55 HDRS 55 Implantable Device 55 mg BID 55 liver histology 55 octreotide LAR 55 #.#/#.# mmHg [001] 55 Psoriasis Area 55 YMRS 55 PLCO 55 Cytogenetic 55 carotid IMT 55 postoperative chemotherapy 55 echocardiographic parameters 55 ADCS CGIC 55 APPRAISE 55 Neoadjuvant 55 myocardial infarction 55 IBDQ 55 echocardiographic 55 A1c levels 55 perioperative complications 55 multicentre randomized 55 left ventricular systolic 55 HIV HCV coinfected 55 liver transaminases 55 R0 resection 55 NEVO ™ 55 locoregional recurrence 55 target vessel revascularization 55 Wound Closure 55 glycated hemoglobin levels 55 subanalysis 55 Hemodynamic 55 Hepatotoxicity 55 Arrhythmias 55 invasive aspergillosis 55 DASISION 55 superficial femoral 54 symptomatic intracranial 54 Laryngeal Cancer 54 mammographic density 54 CDAI score 54 leukocyte count 54 ICD implantation 54 Subgroup analysis 54 ACR# responses 54 achieved ACR# 54 multivariate Cox 54 Xelox 54 IBM WebSphere Sensor 54 troponin T 54 PROTECT II 54 Renal Artery 54 trough FEV1 54 SPIRIT III 54 Prolongs Survival 54 GIK infusion 54 hemoglobin A1c levels 54 Myocardial 54 mITT population 54 oral allopurinol 54 Pharmacokinetic parameters 54 thromboembolic disorders 54 angiotensin converting enzyme inhibitors 54 Ventricular Tachycardia 54 CIMZIA ™ 54 Hb A1C 54 HBeAg negative patients 54 metastatic GIST 54 BOLDER II 54 Stenting Trial CREST 54 undergoing CABG 54 endometrial carcinoma 54 desvenlafaxine succinate 54 Cardiopulmonary bypass 54 aminotransferase ALT 54 acute ischemic 54 FOLFOX4 54 HbA 1c levels 54 atheroma volume 54 prospective multicenter study 54 pharmacokinetics PK 54 gastrointestinal perforations 54 glycated hemoglobin HbA1c 54 myocardial infarctions 54 bivalirudin alone 54 Bloodstream Infections 54 Non inferiority 54 atrioventricular block 54 recurrent coronary 54 Capacity FVC 54 Doxil ® 54 laboratory abnormalities 54 radial artery grafts 54 ENDEAVOR III 54 torsades de pointes 54 REYATAZ r arm 54 urinary albumin 54 HYVET 54 TEAEs 54 segment binary restenosis 54 catheter occlusion 54 receiving prophylactic anticoagulation 54 progression TTP 54 ABSORB trial 54 acute myocardial infarctions 54 mucosal healing 54 Tiotropium 54 CIMZIA TM 54 heparin induced thrombocytopenia 54 NHANES III 54 acute myocardial infarction 54 antithrombotic therapy 54 surrogate endpoint 54 achieved CCyR 54 endometrial hyperplasia 54 NSABP B 54 R# #mg BID 54 ACCORD Lipid 54 stent restenosis 54 evaluable subjects 54 Screening Trial 54 undetectable HBV DNA 54 albumin excretion rate 54 extrapyramidal symptoms 54 cEVR 54 carotid stenosis 54 fatal myocardial infarction 54 p = #.# [003] 54 TAXUS Liberte Stent 54 NIHSS score 54 gout flares 54 Gastrointestinal Stromal Tumors 54 TPV r 54 Pharmacodynamic 54 BENICAR HCT 54 Monotherapy 54 vertebral fracture 54 functional mitral regurgitation 54 ischemic cerebrovascular 54 T1c 54 resuscitated cardiac arrest 54 Endpoints 54 artery stenosis 54 certolizumab 54 percutaneous coronary interventions 54 gadolinium enhancing lesions 54 Malignant Glioma 54 HbA1c levels 54 neoadjuvant chemotherapy 54 Hypertrophy 54 Primary Endpoint 54 bivariate 54 Prostate Cancer Prevention 54 multicenter randomized controlled 54 eplerenone 54 nonsignificant 54 febrile neutropenia 54 Anticoagulation 54 nonvertebral fractures 54 Randomised 54 peginterferon alfa 2a #KD 54 Operative mortality 54 RAPAFLO R 54 Afib 54 defibrillator CRT D 54 SIMPADICO 54 decitabine 54 atorvastatin #mg 54 carotid endarterectomy 54 distant metastasis 54 ascending dose 54 electrophysiologic 54 MARINOL R 54 serum calcium levels 54 CIN2 + 54 number NCT# ClinicalTrials.gov 54 Neuropsychiatric Inventory NPI 54 Ischemic Stroke 54 Therapy Reduces 54 metastatic CRC 54 GOUT 54 multivessel disease 54 Renal Cell Carcinoma RCC 54 nonvertebral fracture 54 CD4 + cell 54 epoetin alpha 54 PEGylated interferon beta 1a 54 multivariable analyzes 54 AA Amyloidosis 54 retinal thickness 54 radical prostatectomy RP 54 Sustained virologic response 54 Nesiritide 54 Functional Outcomes 54 timepoint 54 recurrent atrial fibrillation 54 VADT 54 ACTEMRA TM 54 ASSERT 54 Recurrence 54 Paroxysmal Atrial Fibrillation 54 mg/m2 cohort 54 F FDG PET 54 virologic responses 54 Thrombus 54 azilsartan medoxomil 54 coronary stenting 54 thickness CIMT 54 CYPHER Stent 54 C Reactive Protein 54 lymphocyte counts 54 sirolimus eluting 54 myocardial reperfusion 54 confidence intervals CIs 54 recurrent glioblastoma multiforme 54 death reinfarction 54 riociguat 54 receiving golimumab 54 nonfasting triglyceride levels 53 ‰ ¥ 53 glycemic variability 53 FFR guided 53 CYPHER R Stent 53 bi ventricular pacing 53 Pharmacokinetic PK 53 atherogenic dyslipidemia 53 locoregional 53 Flu Cy 53 radical retropubic prostatectomy 53 BR.# 53 TEVAR 53 covariance ANCOVA 53 mg BID dose 53 hsCRP levels 53 neutropenia dehydration dyspnea 53 mg/m2 dose 53 Myocardial infarction 53 mCi kg 53 Coronary Artery Bypass Surgery 53 Randomized Controlled Trials 53 SCD HeFT 53 MitraClip device 53 Fasting plasma glucose 53 Kaplan Meier curves 53 Initiated Phase 53 multivariable adjusted 53 TLUS 53 crossclamp 53 abdominal adiposity 53 HRCT 53 Diastolic 53 CRBSI 53 alanine aminotransferase 53 logistic regression analysis 53 thrombo embolic 53 Systolic 53 International Prognostic Scoring 53 sinus rhythm 53 cirrhotic patients 53 tumor resection 53 peripheral sensory neuropathy 53 lymph node metastasis 53 seroprotection 53 serum uric acid 53 hypomagnesemia 53 dalteparin 53 hemoglobin A1c HbA1c 53 serum HBV DNA 53 aspartate aminotransferase AST 53 Albuminuria 53 EchoCRT 53 clinicopathological 53 parathyroidectomy 53 KENOSHA AREA CONVENTION 53 Randomized Controlled 53 adenotonsillectomy 53 rt PA 53 Efficacy Results 53 CR CRu 53 TAXUS V 53 International Prostate Symptom 53 ToGA 53 intratumoral 53 fluvastatin 53 UPDRS motor 53 serious cardiovascular thrombotic 53 Double Blind Randomized 53 HORIZONS AMI 53 clinically evaluable population 53 refractory ischemia 53 hemodynamically significant 53 microalbuminuria 53 exploratory endpoints 53 cardiac dysfunction 53 left ventricular dysfunction 53 pain palliation 53 symptomatic carotid stenosis 53 Meta analyzes 53 Intervention Trial 53 hemodynamic measurements 53 coronary stenosis 53 plasma uric acid 53 meta regression 53 UPDRS 53 ST elevation myocardial 53 retrospectively analyzed 53 undergoing Percutaneous Coronary 53 thrombus formation 53 -#.# log# copies mL 53 treat NNT 53 prospective multicenter randomized 53 Montgomery Åsberg Depression 53 hemodilution 53 SPIRIT IV 53 cardiopulmonary bypass CPB 53 prednisone prednisolone 53 NCT# ClinicalTrials.gov 53 serum creatinine levels 53 venous thromboembolic events 53 thrombus aspiration 53 neutropaenia 53 Multidetector CT 53 MACE 53 HOMA IR 53 QIDS SR 53 revascularizations 53 chlorambucil 53 locoregional disease 53 Autologous Stem Cell Transplantation 53 variceal 53 NIS LL 53 lymphopenia 53 Myocardial Infarction MI 53 PSA kinetics 53 microbiological eradication 53 Diaries Diaries 53 estramustine 53 patients evaluable 53 atherosclerotic cardiovascular 53 TAXUS VI 53 ADHF 53 4mg/kg 53 LV ejection fraction 53 GISSI HF 53 eGFR 53 Active Ulcerative Colitis 53 NATRECOR ® 53 Severity Index PASI 53 NEVO 53 Heart Failure Therapies 53 VAPRISOL 53 CHD CVD 53 univariate 53 SLNB 53 elevated creatinine 53 Profile SEP 53 aplastic anemia AA 53 Pulmonary Artery 53 Intracoronary 53 cerebral vasospasm 53 prostate cancer CaP 53 HER2 expression 53 tipranavir 53 AVANDIA 53 Colorectal Cancers 53 MADRS score 53 myocardial viability 53 multicenter randomized placebo controlled 53 antiarrhythmic drug 53 melphalan prednisone 53 HAM D# 53 CVD mortality 53 transurethral resection 53 Randomized Double Blind 53 MERIT ES 53 Heart Rate Variability 53 CAPRIE 53 QTcF 53 TAXUS Liberte stent 53 moderate hepatic impairment 53 aldosterone antagonists 53 endoleaks 53 MADIT CRT trial 53 Randomized Phase 53 plasma HCV RNA 53 nodal metastasis 53 nadolol 53 NIH CPSI 53 resynchronization therapy 53 alteplase 53 morbidity mortality 53 Aortic Stenosis 53 Kaplan Meier method 53 IFN α 53 noninferior 53 BEXXAR Therapeutic Regimen 53 advanced adenomas 53 oncologic outcomes 53 CRT ICD 53 crizotinib PF # 53 genotypic resistance 53 #.#mg/dL 53 abciximab 53 immunohistochemical 53 tumor histology 53 Sorafenib HCC Assessment 53 candesartan 53 ventricular tachyarrhythmias 53 ULORIC 53 ACE inhibitor ramipril 53 EBMT criteria 53 OGTT 53 NNT = 53 GP IIb IIIa inhibitors 53 CCX# 53 Visual Analogue Scale VAS 53 Sentinel Lymph Node Biopsy 53 Anna Krejci Dells 53 tumor progression TTP 53 patients undergoing percutaneous 53 BCIRG 53 CALGB # [002] 53 Demonstrate Significant 53 histologically confirmed 53 Mortality Risk 53 lymphadenectomy 53 Mean Symptom Complex 53 EBUS FNA 53 HDL Cholesterol 53 ventricular dysfunction 53 paroxysmal atrial fibrillation 53 ASCO Breast Cancer 53 noncardiac 53 cytogenic 53 pharmacodynamic 53 P = .# 53 atherothrombotic events 53 reperfusion therapy 53 mg TID 53 ribavirin RBV 53 AJCC 53 evaluating mipomersen 53 CUSTOM III 53 trials RCTs 53 noninferiority 53 leukocyte counts 53 zonisamide SR 53 PREVENT IV 53 kidney allograft 53 lispro alone 53 5 Fluorouracil 53 BARACLUDE r 53 SpO2 53 Endothelial Function 53 liver resection 53 bosentan 53 plus glycoprotein IIb 53 Pelvic Organ Prolapse 53 serologically active SLE 53 Dose Reduction 53 primary endpoint 53 Clostridium difficile Infection 53 stroke myocardial infarction 53 rosuvastatin 53 hypoglycemic events 53 PRoFESS 53 estimated GFR 53 NSTEMI 52 PRADAXA #mg 52 serum estradiol 52 DAPT 52 -#.# log# 52 ARB telmisartan 52 CHARM Added 52 ertapenem 52 TAXUS IV 52 hepatic enzyme 52 simvastatin ezetimibe 52 urine albumin 52 atazanavir ritonavir 52 percutaneous intervention 52 aortic insufficiency 52 left ventricular diastolic 52 Severe Asthma 52 Peginterferon Alfa 2a 52 somatostatin analog 52 glomerular filtration rate 52 #mg/day [001] 52 ejection fractions 52 Predictive Value 52 intraobserver 52 Renal Function 52 Phase III VISTA 52 revascularization 52 intact parathyroid hormone 52 spirometric 52 prospective randomized placebo 52 colorectal carcinoma 52 ACCOMPLISH 52 Scale cognitive subscale 52 IPSS 52 Thrombus Aspiration 52 intracerebral hemorrhage ICH 52 STEMI ST 52 SGRQ 52 perioperatively 52 tumor recurrence 52 clinico pathological 52 Ranolazine 52 ID TLR 52 reoperations 52 Non Inferiority 52 pegylated interferon alfa 2b 52 NYHA class 52 bivalirudin 52 Warfarin Coumadin 52 coronary artery revascularization 52 NSABP C 52 infusional 52 DIARY Federal Reserve 52 National Emphysema Treatment 52 abdominal pain abdominal discomfort 52 histologic 52 univariate analysis 52 nausea photophobia 52 Status Scale EDSS 52 thrombotic complications 52 teriflunomide 52 Vertebral Fractures 52 naïve HCV 52 subgroup analyzes 52 PRECiSE 52 vincristine doxorubicin 52 plus methotrexate 52 DAS# remission 52 valvular disease 52 invasive candidiasis 52 venous thromboembolism 52 occlusive disease 52 EBRT 52 Prostate Cancer Outcomes 52 carotid artery stenting 52 hepatectomy 52 Cimzia TM 52 carotid revascularization